CIPO Patents = 2

EPO Patents = 4 (Patent Applications = 5)

Average Co-Inventor Count = 3.9

ph-index = 9

Forward Citations = 224(Granted Patents)

Location History:

Herbeunont, BE (1998 - 1999)
Brussels, BE (1992 - 2011)
Kraainem, BE (2008 - 2022)

Company Filing History:

25 out of 525

Ludwig Institute for Cancer Research Limited

Universitè Catholique De Louvain

Department D'immunologie Institut Henri Beaufour

Departemente D'immunologie Institut Henri Beaufour

patent

where one patent can have more than one assignee

Years Active: 1992-2022

Loading Chart...

31 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11230603 - Anti-GARP protein (2022-01-25),

2. 10604579 - Antibody against a complex between human GARP and latent TGF-β (2020-03-31),

3. 10138289 - Method for producing antibody using 'naked' expression vector expressing type II transmembrane fusion protein (2018-11-27),

4. 10000572 - Method for inhibiting the immune suppressive function of human T regulatory cells by administering an anti-GARP monoclonal antibody (2018-06-19),

5. 9234042 - Method for producing antibody using 'naked' expression vector expressing type II transmembrane fusion protein (2016-01-12),

6. 7972833 - Isolated nucleic acid molecules which encode T cell inducible factors (TIFs), the proteins encoded, and uses thereof (2011-07-05),

7. 7846652 - Method for identifying a substance which mediates interaction between interleukin 22 and an interleukin 22 receptor (2010-12-07),

8. 7569667 - Isolated soluble IL-TIF/IL-22 receptor or binding protein which binds to IL-TIF/IL-22, and uses thereof (2009-08-04),

9. 7371383 - Recombinant anti-interleukin-9 antibodies (2008-05-13),

10. 7268223 - Isolated nucleic acid molecules which encode a soluble IL-TIF receptor or binding protein which binds to IL-TIF/IL-22, and uses thereof (2007-09-11),

11. 7094570 - Isolated nucleic acid molecules which encode a soluble IL-TIF/IL-22 receptor or binding protein which binds to IL-TIF/IL-22, and uses thereof (2006-08-22),

12. 7081528 - Isolated nucleic acid molecules encoding T cell derived inducible factors (2006-07-25),

13. 7033787 - Isolated cytokine receptor LICR-2 (2006-04-25),

14. 6638512 - Method for treating subjects by using BAGE tumor rejection antigen precursors or tumor rejection antigens (2003-10-28),

15. 6465184 - Isolated nucleic acid molecule encoding peptides which form complexes with MHC molecules HLA-Cw*1601 and uses thereof (2002-10-15),

Title: Jean-Christophe Renauld: Innovator in Protein Research

Introduction

Jean-Christophe Renauld, based in Brussels, Belgium, is a prominent figure in the field of protein research, particularly in the context of cancer therapy and immunology. With an impressive portfolio of 31 patents, Renauld has made significant contributions to medical science, focusing on the interactions of proteins in the presence of transformative growth factor-beta (TGF-β).

Latest Patents

Among his latest innovations is the patent for the Anti-GARP protein, which details a protein that binds to GARP in the presence of TGF-β and explores its potential applications. Another noteworthy invention is an antibody against the complex formed between human GARP and latent TGF-β, which further underlines his dedication to advancing therapeutic options in cancer treatment.

Career Highlights

Renauld has had a distinguished career, working with renowned organizations such as the Ludwig Institute for Cancer Research Limited and Wyeth. His expertise in protein interactions has positioned him as a leader in his field, reflecting his commitment to advancing scientific understanding and applications.

Collaborations

Throughout his career, Renauld has collaborated with esteemed colleagues including Laure Dumoutier and Pierre G. Coulie. These partnerships have allowed him to expand his research impact and innovate in protein studies, contributing to breakthroughs in therapeutic strategies.

Conclusion

With 31 patents to his name, Jean-Christophe Renauld continues to be a driving force in the world of protein research. His work not only paves the way for advancements in cancer treatment but also exemplifies the critical role of innovation in scientific research. As he progresses in his career, his contributions are sure to have lasting effects on the medical community and beyond.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

2 patents (CIPO):

Please report any incorrect information to support@idiyas.com

4 patents (EPO):

Please report any incorrect information to support@idiyas.com

5 patents pending (EPO):

Please report any incorrect information to support@idiyas.com